Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$5.52 USD
+0.46 (9.09%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.53 +0.01 (0.18%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.52 USD
+0.46 (9.09%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.53 +0.01 (0.18%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth D Momentum C VGM
Zacks News
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
by Zacks Equity Research
The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
by Zacks Equity Research
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test
by Zacks Equity Research
QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.
Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases
by Zacks Equity Research
Bayer (BAYRY) enters a strategic deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for addressing eye diseases.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 29.27% and 34.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Adaptive Biotechnologies (ADPT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Adaptive Biotechnologies (ADPT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for February 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for January 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for January 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Do Options Traders Know Something About Adaptive Biotechnologies (ADPT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Adaptive Biotechnologies (ADPT) stock based on the movements in the options market lately.
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Adaptive Biotechnologies (ADPT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.33% and 3.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Work-From-Home Push Drive Microsoft (MSFT) Q4 Earnings?
by Zacks Equity Research
Microsoft's (MSFT) fiscal fourth-quarter results are likely to reflect momentum in Azure, impressive Teams user growth led by coronavirus-induced work-from-home wave and uptick in Surface devices.